Subacromial impingement syndrome Injury, Occupational Diseases, Poisoning Subacromial impingement syndrome
Conditions
Interventions
Participants are randomised to receive one of the following treatments:
1. Subacromial corticosteroid (triamcinolone acetonide) injection combined with a standardised physiotherapy regimen
2. Standard
Sponsors
West Yorkshire Primary Care Research and Development Unit (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 40 years or older with unilateral shoulder pain. Shoulder pain is defined as pain in the shoulder region, including the upper arm, elicited or exacerbated by active or passive shoulder movement.br/>2. Subject rating of pain as moderate or severe on a 3-point scale (mild/moderate/severe) 3. Non-capsular pattern of restriction where capsular pattern is defined as painful and limited passive glenohumeral mobility, lateral rotation must be relatively more restricted than abduction and medial rotation. Some loss of lateral rotation permitted but no more than 25% compared to opposite side. 4. Positive impingement test (Hawkins or Neer)
Exclusion criteria
Exclusion criteria: 1. Unable to give informed consent 2. Known blood coagulation disorders 3. Evidence of referred pain from the cervical spine or internal organs 4. Neurological abnormality of the shoulder 5. History of rheumatoid arthritis, polymyalgia rheumatica or other inflammatory arthritis 6. Bilateral shoulder pain 7. Contraindications to local steroid/lidocaine injection 8. Pregnancy or breastfeeding 9. Previous fracture, dislocation or surgery to shoulder, upper limb, neck, or thorax 10. No previous steroid injections in the symptomatic shoulder in the previous 6 months 11. No previous physiotherapy for the symptomatic shoulder in the previous 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The shoulder pain and disability index (SPADI) at week 12 will be considered the primary outcome | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Participant global assessment of change from baseline will be recorded using a five-point scale 2. Overall health status will be recorded using the Euroqol 3. Information on use of therapeutic interventions from weeks 12 to 24 will be recorded | — |
Countries
United Kingdom
Outcome results
None listed